PMID- 21501118
OWN - NLM
STAT- MEDLINE
DCOM- 20111028
LR  - 20220408
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 78
IP  - 1
DP  - 2011 Jul
TI  - Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug 
      hypersensitivity.
PG  - 11-20
LID - 10.1111/j.1399-0039.2011.01649.x [doi]
AB  - HLA-B57 and HLA-B58 are major histocompatibility class (MHC)-I allotypes that are 
      potentially predictive of important clinical immune phenotypes. HLA-B*5701 is 
      strongly associated with hypersensitivity to the HIV drug abacavir, liver 
      toxicity from the antibiotic flucloxacillin and is a marker for slow progression 
      of HIV AIDS. HLA-B*5801 is associated with hypersensitivity to allopurinol used 
      to treat hyperuricaemia and recurrent gout. Here we describe a monoclonal 
      antibody (mAb) specific for HLA-B57 and HLA-B58 that provides an inexpensive and 
      sensitive screen for these MHC-I allotypes. The usefulness of HLA-B57 screening 
      for prediction of abacavir hypersensitivity was shown in three independent 
      laboratories, including confirmation of the mAb sensitivity and specificity in a 
      cohort of patients enrolled in the PREDICT-1 trial. Our data show that patients 
      who test negative by mAb screening comprise 90%-95% of all individuals in most 
      human populations and require no further human leukocyte antigen (HLA) typing. 
      Patients who test positive by mAb screening should proceed to high-resolution 
      typing to ascertain the presence of HLA-B*5701 or HLA-B*5801. Hence, mAb 
      screening provides a low-cost alternative to high-resolution typing of all 
      patients and lends itself to point-of-care diagnostics and rapid ascertainment of 
      low-risk patients who can begin immediate therapy with abacavir, flucloxacillin 
      or allopurinol.
CI  - (c) 2011 John Wiley & Sons A/S.
FAU - Kostenko, L
AU  - Kostenko L
AD  - Department of Microbiology and Immunology, The University of Melbourne, 
      Parkville, Victoria, Australia. lyudmila@unimelb.edu.au
FAU - Kjer-Nielsen, L
AU  - Kjer-Nielsen L
FAU - Nicholson, I
AU  - Nicholson I
FAU - Hudson, F
AU  - Hudson F
FAU - Lucas, A
AU  - Lucas A
FAU - Foley, B
AU  - Foley B
FAU - Chen, K
AU  - Chen K
FAU - Lynch, K
AU  - Lynch K
FAU - Nguyen, J
AU  - Nguyen J
FAU - Wu, A H B
AU  - Wu AH
FAU - Tait, B D
AU  - Tait BD
FAU - Holdsworth, R
AU  - Holdsworth R
FAU - Mallal, S
AU  - Mallal S
FAU - Rossjohn, J
AU  - Rossjohn J
FAU - Bharadwaj, M
AU  - Bharadwaj M
FAU - McCluskey, J
AU  - McCluskey J
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20110419
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B57 antigen)
RN  - 0 (HLA-B58)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Antibodies, Monoclonal/biosynthesis/isolation & 
      purification/metabolism/pharmacology
MH  - Antibody Formation
MH  - Antibody Specificity
MH  - Cells, Cultured
MH  - Drug Hypersensitivity/genetics/immunology/*prevention & control
MH  - Enzyme-Linked Immunosorbent Assay
MH  - HLA-B Antigens/*analysis/genetics/immunology
MH  - Histocompatibility Testing/methods
MH  - Humans
MH  - Mass Screening/*methods
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Models, Molecular
MH  - Molecular Sequence Data
MH  - Time Factors
EDAT- 2011/04/20 06:00
MHDA- 2011/10/29 06:00
CRDT- 2011/04/20 06:00
PHST- 2011/04/20 06:00 [entrez]
PHST- 2011/04/20 06:00 [pubmed]
PHST- 2011/10/29 06:00 [medline]
AID - 10.1111/j.1399-0039.2011.01649.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2011 Jul;78(1):11-20. doi: 10.1111/j.1399-0039.2011.01649.x. 
      Epub 2011 Apr 19.